Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist
نویسندگان
چکیده
BACKGROUND The pathologic diagnosis of isolated myocarditis without pericardial involvement is uncommonly encountered in systemic onset Juvenile Idiopathic Arthritis (soJIA). CASE An eleven year-old boy with soJIA died suddenly while being treated with the interleukin 1 (IL-1) receptor inhibitor, anakinra. His autopsy revealed an enlarged heart and microscopic findings were consistent with myocarditis, but not pericarditis. Viral PCR testing performed on his myocardial tissue was negative. CONCLUSION This case illustrates myocarditis as a fatal complication of soJIA, potentially enabled by anakinra.
منابع مشابه
R202Q Mutation of Mediterranean Fever Gene in Iranian patients with Systemic-onset Juvenile Idiopathic Arthritis
Background: Systemic-onset Juvenile Idiopathic Arthritis (SoJIA) is an autoinflammatory disease with complex genetic trait starts in children less than 16 years of age with fever and cutaneous rash. Despite, the main genetic factors that may play a role in SoJIA have not yet been identified. High level of interleukin-1beta in the blood of SoJIA patients has been reported. The production and sec...
متن کاملInterleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis.
PURPOSE OF REVIEW Systemic-onset juvenile idiopathic arthritis is a severe and steroid-dependent disease that sometimes progresses to a fatal disease, macrophage activation syndrome. The investigation of proinflammatory cytokine levels revealed the increases of interleukin 6 in serum of systemic-onset disease. To avoid the disease progression and the adverse events of high-dose corticosteroids,...
متن کاملMacrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
Introduction Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Changes in therapies, including biologics, have been associated with the onset of MAS. Interleukin-6 (IL-6) plays a major pathogenic role in sJIA; data in animals suggest that high IL-6 levels contribute to the triggering of MAS [1]. Treatment with the ...
متن کاملTreatment of systemic-onset juvenile arthritis with canakinumab
Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and descri...
متن کاملThe use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
We report a case of a 6 year old girl with systemic onset juvenile idiopathic arthritis which presented at age of 3 years refractory to disease-modifying antirheumatic drugs and anakinra. During the first hospitalization a ganglioneuroblastoma (GNB) was diagnosed and consequently treated. During the SFOP treatment protocol for GNB our patient continued with low grade fever, but soon after the t...
متن کامل